Cancer Research Annual Meeting 2010 2010 Workshops
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yokoyama, Y.
Right arrow Articles by Ramakrishnan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yokoyama, Y.
Right arrow Articles by Ramakrishnan, S.
[Cancer Research 60, 4362-4365, August 15, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Effect of Endostatin on Spontaneous Tumorigenesis of Mammary Adenocarcinomas in a Transgenic Mouse Model1

Yumi Yokoyama, Jeffrey E. Green, Vikas P. Sukhatme and S. Ramakrishnan2

Departments of Pharmacology [Y. Y., S. R.] and Obstetrics and Gynecology [S. R.] and Comprehensive Cancer Center [S. R.], University of Minnesota, Minneapolis, Minnesota 55455; Laboratory of Cell Regulation and Carcinogenesis, Division of Basic Science, National Cancer Institute, Bethesda, Maryland 20892 [J. E. G.]; and Renal Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215 [V. P. S.]

A transgenic mouse model was used to evaluate the effect of endostatin treatment on spontaneous tumorigenesis. In this model system, female mice develop multiple mammary adenocarcinomas and male mice develop prostate cancer. Female mice treated with mouse endostatin during a 12–15-week period showed delayed tumor development by 4–6 weeks and significantly decreased tumor burden. Furthermore, endostatin treatment reduced the number of malignant lesions per mouse. In a separate set of experiments, male mice treated with endostatin showed a survival advantage, and their life spans were prolonged by 10.5 weeks over control animals. These data demonstrate that mouse endostatin is effective in delaying spontaneous tumor development and growth.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Mustafa and W. D. Kruger
Suppression of Tumor Formation by a Cyclooxygenase-2 Inhibitor and a Peroxisome Proliferator-Activated Receptor {gamma} Agonist in an In vivo Mouse Model of Spontaneous Breast Cancer
Clin. Cancer Res., August 1, 2008; 14(15): 4935 - 4942.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Liu, S. Varghese, and S. D. Rabkin
Oncolytic Herpes Simplex Virus Vector Therapy of Breast Cancer in C3(1)/SV40 T-antigen Transgenic Mice
Cancer Res., February 15, 2005; 65(4): 1532 - 1540.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Iizasa, H. Chang, M. Suzuki, M. Otsuji, S. Yokoi, M. Chiyo, S. Motohashi, K. Yasufuku, Y. Sekine, A. Iyoda, et al.
Overexpression of Collagen XVIII Is Associated with Poor Outcome and Elevated Levels of Circulating Serum Endostatin in Non-Small Cell Lung Cancer
Clin. Cancer Res., August 15, 2004; 10(16): 5361 - 5366.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. T. Beck, N. Y. Chen, K. J. Franek, and W. Y. Chen
Prolactin Antagonist-endostatin Fusion Protein as a Targeted Dual-Functional Therapeutic Agent for Breast Cancer
Cancer Res., July 1, 2003; 63(13): 3598 - 3604.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
C. Kavanaugh and J. E. Green
The Use of Genetically Altered Mice for Breast Cancer Prevention Studies
J. Nutr., July 1, 2003; 133(7): 2404S - 2409.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Thomas, R. Z. Arzoomanian, D. Alberti, R. Marnocha, F. Lee, A. Friedl, K. Tutsch, A. Dresen, P. Geiger, J. Pluda, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors
J. Clin. Oncol., January 15, 2003; 21(2): 223 - 231.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
J.-i. Hanai, J. Gloy, S. A. Karumanchi, S. Kale, J. Tang, G. Hu, B. Chan, R. Ramchandran, V. Jha, V. P. Sukhatme, et al.
Endostatin is a potential inhibitor of Wnt signaling
J. Cell Biol., August 5, 2002; 158(3): 529 - 539.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Calvo, A. L. Feldman, S. K. Libutti, and J. E. Green
Adenovirus-mediated Endostatin Delivery Results in Inhibition of Mammary Gland Tumor Growth in C3(1)/SV40 T-Antigen Transgenic Mice
Cancer Res., July 15, 2002; 62(14): 3934 - 3938.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Iughetti, O. Suzuki, P. H. C. Godoi, V. A. Ferreira Alves, A. L. Sertie, T. Zorick, F. Soares, A. Camargo, E. S. Moreira, C. di Loreto, et al.
A Polymorphism in Endostatin, an Angiogenesis Inhibitor, Predisposes for the Development of Prostatic Adenocarcinoma
Cancer Res., October 1, 2001; 61(20): 7375 - 7378.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.